arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Arcutis Biotherapeutics, Inc.

ARQT

$26.36 ▼ -1.41 (-5.06%) at close

9 Visible periods

29 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Arcutis Biotherapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.4B

Dividend Yield —

Revenue Growth 91.3% ↘

Op. Margin -3.3% ↗

ROIC -3.2% ↗

FCF / Share $-0.05 ↗

Trailing P/E —

Price / Book 17.2x

FCF Yield —

Debt / Equity 0.58

info Valuation on last close. End-of-day price, Sep 23, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$376.07M

↑ +91.3% —

Net Income Profit after all expenses

$-16.14M

↑ +88.5% —

Operating Margin Operating profit as % of sales

-3.3%

↑ +95.0% 22th

FCF / Share Free cash flow per share

$-0.05

↑ +94.7% —

Long-Term Debt Long-term obligations

$108.96M

↑ +1.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↑

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue Growth YoY (%)	91.3% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1042%)	229.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2772%)	1517.1% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+18864%)	—	—	—	—	—	—
EPS Growth YoY (%)	88.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	69.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	33.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-35.4% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-10.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	88.5% Excellent ↑ Excellent Improving Year-over-year change in net income	46.6% Excellent ↑ Excellent Improving Year-over-year change in net income	15.8% Good ↑ Good Improving Year-over-year change in net income	-50.9% Weak ↑ Weak Improving Year-over-year change in net income	-52.1% Weak ↑ Weak Improving Year-over-year change in net income	-223.1% Weak Weak Year-over-year change in net income	-118.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	94.7% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	74.0% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	23.8% Good ↑ Good Improving Year-over-year change in free cash flow	-31.9% Weak Weak Year-over-year change in free cash flow	-11.9% Weak Weak Year-over-year change in free cash flow	—	—	—	—
Revenue CAGR 3Y (%)	367.3% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Operating Margin (%) (%)	-3.3% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-122%)	-65.3% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-536%)	-404.5% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2797%)	—	—	—	—	—	—
Profit Margin (%) (%)	-4.3% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-136%)	-71.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-694%)	-439.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3765%)	—	—	—	—	—	—
FCF Margin (%) (%)	-1.7% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-57.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-415.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—
FCF / Net Income (x)	0.39x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.03x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	-3.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-38.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-65.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-58.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-44.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-39.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	52.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	65.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-2.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-36.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-70.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-67.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-50.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-45.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-40.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-8.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-157%)	-88.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-693%)	-295.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-2071%)	-148.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1091%)	-69.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-562%)	-50.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-434%)	64.6% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+331%)	80.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+435%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Debt to Equity (x)	0.58x Good ↓ Good Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: At sector avg	0.68x Fair ↓ Fair Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+13%)	2.28x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+279%)	0.94x Fair ↑ Fair Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+57%)	0.24x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-59%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—	—
Interest Coverage (x)	-1.18x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-5.78x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-9.48x Weak Weak Operating income divided by interest expense Optimal: > 5x	-19.27x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—
Net Debt (USD)	$66.05M	$35.87M	$113.40M	$144.13M	$-24.10M	$-65.08M	$-63.34M	—	—
Debt / EBITDA (x)	-9.45x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.84x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.84x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.66x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.35x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue per Share (USD)	$2.96	$1.62	$0.86	$0.07	$0.00	—	—	—	—
Basic EPS, GAAP (USD)	$-0.13	$-1.16	$-3.78	$-5.66	$-4.18	$-3.80	—	—	—
Free Cash Flow per Share (USD)	$-0.05	$-0.93	$-3.57	$-4.69	$-3.55	$-3.18	—	—	—
Book Value per Share (USD)	$1.54	$1.34	$0.92	$3.43	$5.92	$6.24	$-30.66	—	—
Tangible Book Value per Share (USD)	$1.42	$1.26	$0.85	$3.32	$5.92	$6.24	$-30.66	—	—
Basic Weighted Avg Shares (shares)	127.23M	120.96M	69.31M	55.03M	49.41M	35.67M	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$281.39M	$254.81M	$283.76M	$399.60M	$369.45M	$270.22M	$101.24M	—	—
LT Debt (USD)	$108.96M	$107.20M	$201.80M	$197.77M	$72.35M	$0.00	—	—	—
Total Equity (USD)	$189.48M	$157.54M	$88.67M	$209.58M	$297.68M	$270.62M	$-65.03M	$-23.99M	$-4.99M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Sales/Revenue/Turnover (USD)	$376.07M	$196.54M	$59.61M	$3.69M	$0.00	—	—	—	—
Depreciation Expense (USD)	$700.00K	$600.00K	$771.00K	$622.00K	$454.00K	$122.00K	$68.00K	$0.00	—
Net Income, GAAP (USD)	$-16.14M	$-140.04M	$-262.14M	$-311.46M	$-206.36M	$-135.68M	$-42.00M	$-19.25M	—
Operating Cash Flow (USD)	$-5.62M	$-112.16M	$-247.06M	$-257.71M	$-174.63M	$-113.03M	$-42.84M	$-14.09M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 32 quarters

Arcutis Biotherapeutics, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ARQT with peers